Texas A&M University Health Science Center and Wave Neuroscience have started the second phase of a clinical trial on post-traumatic stress disorder (PTSD) that will investigate the safety and efficacy of magnetic electroencephalogram-guided resonance therapy (MeRT).
MeRT is a personalized, noninvasive, nonpharmacological investigative treatment. The trial is examining how well MeRT treats 175 patients for PTSD with or without persistent postconcussion symptoms from traumatic brain injury.
This second phase looks at a larger and more diverse group of patients where active or simulated MeRT will be provided during daily visits to the study site over a five-week period. After five weeks, participants may receive up to two weeks of daily active stimulation sessions, and additional data collection may be completed remotely. Enrollment is expected to close in spring 2023.
